CSF3R mutations are associated with response of chronic neutrophilic leukemia to JAK inhibitors such as ruxilitinib and provide another possible avenue for targeted therapy in ETP-ALL. The gene discussed is CSF3R; the disease is acute lymphoblastic leukemia.